Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nerandomilast in people with a family history of pulmonary fibrosis and early interstitial lung abnormalities
NL-OMON59187Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of nerandomilast in pulmonary fibrosis (PF) and interstitial lung disease (ILD), sponsored by Boehringer Ingelheim. Started Apr 2026; status: recruiting.
02
Drugs
nerandomilast
03
Conditions
pulmonary fibrosis (PF)interstitial lung disease (ILD)
Beyond the preview
Go deeper on NL-OMON59187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59187.